Aims & Scope:

The integrity of bone and skeleton tissue is preserved by a balance maintaining between the activity of osteoblasts conducted bone forming (osteogenesis) and osteoclasts conducted bone resorbing (osteoclastogenesis), which ensures no net change in bone mass. As the consequence of the discoveries of RANKL, study for osteoclastogenesis stepped into a new era. RANKL binding with its receptor RANK recruits TRAFs to the cytoplasmic domain of RANK. This engagement leads to the activation of series signaling cascades with downstream targets, which including: ERK, p38, JNK, PI3K and IκB kinase. Subsequently, crucial osteoclastogenic transcription factors, c-Fos and NFATc1 are activated, which further induce the expression of osteoclast specific genes expression, including TRAP and cathepsin K, and DC-STAMP. Finally, lead to bone loss. Therefore, the aim of this special issue in “Current Drug Targets” is focusing on recent novel understanding for signaling target involved in osteoclastogenesis and frontier therapeutic drugs development (including: clinical treatment medicines and drugs still in trail).

Schedule:

- Manuscript submission deadline: May 2019

Contacts:

Guest Editor: Dr. Lingbo Kong
Affiliation: Honghui hospital, Xi'an Jiaotong University, school of medicine, xi'an China, 710054
Email: lingbokong@163.com

Any queries should be addressed to cdt@benthamscience.net